Drug Profile
Research programme: neuropathic pain gene therapy - Avigen
Alternative Names: AV333Latest Information Update: 22 May 2009
Price :
$50
*
At a glance
- Originator University of Colorado at Boulder
- Developer Avigen
- Class Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 22 May 2009 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
- 26 Nov 2007 Preclinical development is ongoing
- 07 Sep 2005 AV 333 is available for licensing in Europe and Asia (http://www.avigen.com)